Assessment of ROP Incidence and Factors in Preterm Infants in Turkey

Overview

This multicenter study evaluates the incidence and risk factors for retinopathy of prematurity (ROP) in preterm infants with birth weights over 1500 g or gestational ages beyond 32 weeks in Turkey. It highlights the role of being small for gestational age and multiple systemic comorbidities in ROP development.

Background

Retinopathy of prematurity (ROP) is a significant cause of preventable blindness in children globally, with varying incidence rates influenced by neonatal care quality. In Turkey, recent guidelines have expanded ROP screening criteria for preterm infants born before 34 weeks or with a birth weight under 1700 g.

Data Highlights

No numerical data available in the provided source.

Key Findings

• ROP can occur in preterm infants with greater gestational ages and larger birth weights.
• Being small for gestational age and having multiple systemic comorbidities are significant risk factors for ROP development.
• Current Turkish guidelines recommend ROP screening for preterm infants born before 34 weeks or with a birth weight under 1700 g.

Clinical Implications

Clinicians should consider systemic risk factors when assessing preterm infants for ROP, particularly those who are small for gestational age.

Conclusion

The findings of this study highlight the need for tailored ROP screening guidelines that account for specific risk factors in preterm infants.

Related Resources & Content

1. Turkish Neonatal Society, TR-ROP 2 Study, 2023 -- Assessment of the Incidence, Contributing Factors, and Outcomes of Retinopathy of Prematurity
2. Frontiers in Pediatrics — Analysis of influencing factors for progression from type 2 to type 1 in retinopathy of prematurity
3. Frontiers in Pediatrics — Optimizing retinopathy of prematurity screening in China using a single objective criterion: a 10-year retrospective analysis
4. Retinal Physician — Adult ROP: Late Complications of Retinopathy of Prematurity
5. the ophthalmologist — Maternal Diabetes and the Hidden Risk of ROP
6. RCPCH Screening of retinopathy of prematurity guideline template
7. https://todnet.org/en/DATA/files/ROP-guideline_19082025.pdf
8. Long-Term Retinopathy of Prematurity Outcomes with Mandated Screening Interval and Grader Continuity at a High-Volume Quaternary Center - ScienceDirect
9. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity
10. FINAL RESULTS OF THE EARLY TREATMENT FOR RETINOPATHY OF PREMATURITY (ETROP) RANDOMIZED TRIAL - PMC
11. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial - PMC
12. Different ranibizumab dosages for retinopathy of prematurity: 5-year follow-up data of the randomised, controlled CARE-ROP Study
13. Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity | New England Journal of Medicine
14. Impact of anti‐VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta‐analysis - PMC
15. MALPRACTICE AND THE QUALITY OF CARE IN RETINOPATHY OF PREMATURITY (AN AMERICAN OPHTHALMOLOGICAL SOCIETY THESIS) - PMC